| Autor: |
Wiedenmann, Bertram, Reichardt, Peter, Räth, Ulrich, Theilmann, Lorenz, Schüle, Birgit, Ho, Anthony, Schlick, Erich, Kempeni, Joachim, Hunstein, Werner, Kommerell, Burkhard |
| Zdroj: |
Journal of Cancer Research & Clinical Oncology; 1989, Vol. 115 Issue 2, p189-192, 4p |
| Abstrakt: |
Fifteen patients with advanced metastatic adenocarcinomas were treated in a phase-I study with continuous intravenous 24h infusion of recombinant tumor necrosis factor α (TNF-α) in order to determine the maximum tolerated dose (MTD) and associated side-effects. Patients received 40-400 μg/m TNF-α once (arm A) or twice (arm B) weekly for a scheduled treatment period of 2 months. The observed systemic side-effects resembled those reported for interferons and included fever, chills, fatigue, headaches, myalgias, thrombocytopenia, prostration, and malaise. Dose-limiting toxicities, resulting in a median MTD of 200 μg/m for 24h, were fever, chills, fatique, myalgias, and thrombocytopenia. Out of 15 patients, 11 showed tumor progression, and 3 sustained in no change for over 2 months of treatment. A minor response was seen in 1 patient with a colorectal carcinoma and liver metastases. To reduce side-effects, patients were treated either with paracetamol or indomethacin. Higher MTDs were observed in patients treated with indomethacin. No detectable plasma TNF-α levels or TNF antibodies were measured under therapy (plasma TNF-α<20 pg/ml). We conclude that TNF-α appears to have some antineoplastic activity in patients with adenocarcinomas since 4 patients remained in no change or showed a minor response. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink